(Q36858232)

16 August 2017

1 reference

title

Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor (English)

1 reference

16 August 2017

Suzanne George

1

1 reference

16 August 2017

1 July 2007

1 reference

16 August 2017

Current Oncology Reports

1 reference

16 August 2017

9

1 reference

16 August 2017

4

1 reference

16 August 2017

323-327

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-007-0040-1

16 August 2017

0 references

cites work

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-007-0040-1

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-007-0040-1

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

21 January 2018

1 reference

12 December 2020

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

12 December 2020

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

1 reference

12 December 2020

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

1 reference

12 December 2020

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

Biology of gastrointestinal stromal tumors.

1 reference

12 December 2020

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

12 December 2020

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

12 December 2020

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

12 December 2020

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

1 reference

12 December 2020

Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.

1 reference

12 December 2020

Cutaneous side-effects of kinase inhibitors and blocking antibodies

1 reference

12 December 2020

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

12 December 2020

Management of malignant gastrointestinal stromal tumours

1 reference

12 December 2020

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

1 reference

12 December 2020

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

1 reference

12 December 2020

SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models

1 reference

12 December 2020

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden

1 reference

12 December 2020

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

12 December 2020

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

12 December 2020

Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site

1 reference

12 December 2020

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

12 December 2020

The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels

1 reference

12 December 2020

Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases

1 reference

12 December 2020

Gastrointestinal stromal tumors: recent advances in understanding of their biology

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans

1 reference

12 December 2020

10.1007/S11912-007-0040-1

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17588358